The standard treatment approach for relapsed or refractory (RR) classical Hodgkin’s lymphoma (HL) after failure of first-line treatment is second-line therapy with the aim of achieving complete remission (CR), followed by consolidation with high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT). Researchers investigated whether transplantation can be dispensed with in the future under certain conditions.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal
Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)
- Pain and autism